Rising Tide Lifts Many Ships In Wake Of Eisai/Biogen’s Lecanemab Readout

Firms Boosted Regardless Of Alzheimer’s Drugs’ Mechanisms

 
• By Mandy Jackson

Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.

Boats competing in a sailing regatta in the Mediterranean Sea off Turkey
Lilly and Roche, neck-and-neck with Eisai and Biogen, also rose on the Clarity AD data • Source: Shutterstock

More from Clinical Trials

More from R&D